NextCure, Inc.

NasdaqGS:NXTC Voorraadrapport

Marktkapitalisatie: US$37.2m

NextCure Inkomsten in het verleden

Verleden criteriumcontroles 0/6

NextCure's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 64.9% per year.

Belangrijke informatie

-17.8%

Groei van de winst

2.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-64.9%
Rendement op eigen vermogen-71.7%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Jul 17
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Mar 23
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Dec 09
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Aug 23
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

May 10
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Aug 09
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

NextCure GAAP EPS of -$0.59

Aug 04

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

May 02
We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure: Large Upside With Downside Protected By Cash Pile

Sep 29

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12
Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08
NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure provides update on NC318 clinical program

Dec 17

Opbrengsten en kosten

Hoe NextCure geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:NXTC Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-611747
31 Mar 240-641948
31 Dec 230-632048
30 Sep 230-662149
30 Jun 230-702251
31 Mar 230-702151
31 Dec 220-752254
30 Sep 220-742292
30 Jun 220-732178
31 Mar 220-732153
31 Dec 210-692150
30 Sep 210-68200
30 Jun 210-66200
31 Mar 210-631812
31 Dec 2022-37170
30 Sep 2024-32160
30 Jun 2026-24130
31 Mar 2027-18120
31 Dec 196-34100
30 Sep 194-3080
30 Jun 193-2760
31 Mar 191-2440
31 Dec 180-2330

Kwaliteitswinsten: NXTC is currently unprofitable.

Groeiende winstmarge: NXTC is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: NXTC is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.

Versnelling van de groei: Unable to compare NXTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: NXTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: NXTC has a negative Return on Equity (-71.72%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden